Structural approaches to obtain kinase selectivity.

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Structural Biology

Background:

• Kinase inhibitors are crucial for treating various diseases, but achieving clinical efficacy requires high selectivity.
• Current drug discovery relies on structural, biophysical, and computational methods to design selective inhibitors.
• Emergence of resistance mutations poses a significant hurdle in kinase inhibitor therapy.

Purpose of the Study:

• To review structure-based approaches in kinase inhibitor development.
• To highlight examples of kinase inhibitors currently in clinical trials.
• To discuss strategies for generating selective inhibitors and overcoming drug resistance.

Main Methods:

• Structure-based drug design
• Analysis of clinical trial data for kinase inhibitors
• Review of lead generation strategies including fragment-based approaches and novel chemical probes

Main Results:

• Structure-based approaches have informed the development of clinically relevant kinase inhibitors like ARQ197 (cMet inhibitor) and ponatinib (Bcr-Abl inhibitor).
• Resistance mutations present a significant challenge that necessitates the development of next-generation inhibitors.
• Fragment-based approaches and targeted site inhibition show promise for developing selective kinase inhibitors.

Conclusions:

• Structure-based design is a powerful strategy for developing selective kinase inhibitors.
• Overcoming resistance and achieving selectivity remain key challenges in kinase drug discovery.
• Novel strategies like fragment-based design and metal-based probes offer new avenues for developing effective kinase inhibitors.